AAAAAA

   
Results: 1-25 | 26-35 |
Results: 26-35/35
Search for focus in patients with fever of unknown origin: Is F-18-FDG-PEThelpful?
Authors: Lorenzen, J Buchert, R Bleckmann, C Munchow, N Bohuslavizki, KH
Citation: J. Lorenzen et al., Search for focus in patients with fever of unknown origin: Is F-18-FDG-PEThelpful?, ROFO-F RONT, 171(1), 1999, pp. 49-53
F-18-FDG for detecting occult primary tumors in patients with lymph node metastases in the neck.
Authors: Bohuslavizki, KH Klutmann, S Sonnemann, U Thoms, J Kroger, S Werner, JA Mester, J Clausen, M
Citation: Kh. Bohuslavizki et al., F-18-FDG for detecting occult primary tumors in patients with lymph node metastases in the neck., LARY RH OTO, 78(8), 1999, pp. 445-449
Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model
Authors: Bohuslavizki, KH Klutmann, S Jenicke, L Brenner, W Feyerabend, B Henze, E Clausen, M
Citation: Kh. Bohuslavizki et al., Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model, INT J RAD O, 45(1), 1999, pp. 181-186
Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging
Authors: Brenner, W Klomp, HJ Bohuslavizki, KH Szonn, B Kampen, WU Henze, E
Citation: W. Brenner et al., Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging, EUR J NUCL, 26(12), 1999, pp. 1567-1571
Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment - Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer
Authors: Bohuslavizki, KH Klutmann, S Brenner, W Kroger, S Buchert, R Bleckmann, C Mester, J Henze, E Clausen, M
Citation: Kh. Bohuslavizki et al., Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment - Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer, STRAH ONKOL, 175, 1999, pp. 6-12
Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer
Authors: Bohuslavizki, KH Klutmann, S Bleckmann, C Brenner, W Lassmann, S Mester, J Henze, E Clausen, M
Citation: Kh. Bohuslavizki et al., Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer, STRAH ONKOL, 175(2), 1999, pp. 57-61
Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma
Authors: Klutmann, S Bohuslavizki, KH Tietje, N Kroger, S Behnke, A Brenner, W Mester, J Henze, E Clausen, M
Citation: S. Klutmann et al., Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma, J NUCL MED, 40(8), 1999, pp. 1246-1251
Lymphoscintigraphy in tumors of the head and neck using double tracer technique
Authors: Klutmann, S Bohuslavizki, KH Brenner, W Hoft, S Kroger, S Werner, JA Henze, E Clausen, M
Citation: S. Klutmann et al., Lymphoscintigraphy in tumors of the head and neck using double tracer technique, J NUCL MED, 40(5), 1999, pp. 776-782
Effect of attenuation correction on lesion detectability in FDG PET of breast cancer
Authors: Bleckmann, C Dose, J Bohuslavizki, KH Buchert, R Klutmann, S Mester, J Janicke, F Clausen, M
Citation: C. Bleckmann et al., Effect of attenuation correction on lesion detectability in FDG PET of breast cancer, J NUCL MED, 40(12), 1999, pp. 2021-2024
Quality assurance in PET: Evaluation of the clinical relevance of detectordefects
Authors: Buchert, R Bohuslavizki, KH Mester, J Clausen, M
Citation: R. Buchert et al., Quality assurance in PET: Evaluation of the clinical relevance of detectordefects, J NUCL MED, 40(10), 1999, pp. 1657-1665
Risultati: 1-25 | 26-35 |